- Home
- JNJ
JNJ
Johnson & Johnson
as 11-21-2024 12:37pm EST
| Founded: | 1886 | Country: | United States |
| Employees: | N/A | City: | NEW BRUNSWICK |
| Market Cap: | N/A | IPO Year: | 1944 |
| Target Price: | $175.64 | AVG Volume (30 days): | 7.0M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 6.04 | EPS Growth: | -54.32 |
| 52 Week Low/High: | $143.13 - $168.85 | Next Earning Date: | 10-15-2024 |
| Revenue: | $87,696,000,000 | Revenue Growth: | 4.77% |
| Revenue Growth (this year): | 5.29% | Revenue Growth (next year): | 2.83% |
Stock Insider Trading Activity of Johnson & Johnson (JNJ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Decker Robert J | JNJ | VP Corporate Controller | Aug 30 '24 | Sell | $165.06 | 5,635 | $930,113.10 | 18,973 |
Latest Johnson & Johnson News
JNJ Breaking Stock News: Dive into JNJ Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Update: Market Chatter: Johnson & Johnson, Merck Cut Jobs in China
MT Newswires
a day ago
Sector Update: Health Care Stocks Advance Wednesday Afternoon
MT Newswires
a day ago
Market Chatter: Johnson & Johnson, Merck Cut Jobs in China
PR Newswire
2 days ago
Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting
Zacks
2 days ago
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
BioPharma Dive
2 days ago
J&J pill clears skin in two late-stage psoriasis studies
Clinical Trials Arena
2 days ago
Johnson & Johnson reports topline outcomes from trial of icotrokinra for psoriasis
PR Newswire
3 days ago
Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
Compare JNJ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JNJ Johnson & Johnson - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.